research The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
This study found that the antiandrogen drug enzalutamide reduced TMPRSS2 levels and significantly decreased SARS-CoV-2 entry and infection in lung cells, supporting further clinical trials for COVID-19 treatment.


